CN112399973B - 二聚体及其用途 - Google Patents

二聚体及其用途 Download PDF

Info

Publication number
CN112399973B
CN112399973B CN201980037301.2A CN201980037301A CN112399973B CN 112399973 B CN112399973 B CN 112399973B CN 201980037301 A CN201980037301 A CN 201980037301A CN 112399973 B CN112399973 B CN 112399973B
Authority
CN
China
Prior art keywords
ser
gly
val
isvd
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980037301.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN112399973A (zh
Inventor
徐霆
郭康平
杨东
王媲琳
金宇灏
汪皛皛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Alphamab Co Ltd
Original Assignee
Suzhou Alphamab Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Alphamab Co Ltd filed Critical Suzhou Alphamab Co Ltd
Priority to CN202211470101.6A priority Critical patent/CN115991787A/zh
Publication of CN112399973A publication Critical patent/CN112399973A/zh
Application granted granted Critical
Publication of CN112399973B publication Critical patent/CN112399973B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980037301.2A 2018-06-05 2019-06-04 二聚体及其用途 Active CN112399973B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211470101.6A CN115991787A (zh) 2018-06-05 2019-06-04 二聚体及其用途

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/090012 2018-06-05
CN2018090012 2018-06-05
CN2019086821 2019-05-14
CNPCT/CN2019/086821 2019-05-14
PCT/CN2019/089980 WO2019233413A1 (en) 2018-06-05 2019-06-04 Dimer and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202211470101.6A Division CN115991787A (zh) 2018-06-05 2019-06-04 二聚体及其用途

Publications (2)

Publication Number Publication Date
CN112399973A CN112399973A (zh) 2021-02-23
CN112399973B true CN112399973B (zh) 2022-12-16

Family

ID=68769178

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980037301.2A Active CN112399973B (zh) 2018-06-05 2019-06-04 二聚体及其用途
CN202211470101.6A Pending CN115991787A (zh) 2018-06-05 2019-06-04 二聚体及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202211470101.6A Pending CN115991787A (zh) 2018-06-05 2019-06-04 二聚体及其用途

Country Status (6)

Country Link
US (2) US12281163B2 (https=)
EP (1) EP3802613A4 (https=)
JP (1) JP7359785B2 (https=)
CN (2) CN112399973B (https=)
TW (1) TWI831789B (https=)
WO (1) WO2019233413A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11377497B2 (en) * 2017-01-23 2022-07-05 Suzhou Alphamab Co., Ltd. PD-L1 binding polypeptide or composite
CN112399973B (zh) * 2018-06-05 2022-12-16 江苏康宁杰瑞生物制药有限公司 二聚体及其用途
US12565531B2 (en) 2019-12-04 2026-03-03 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Bispecific fusion protein for tumor treatment
WO2021110107A1 (en) * 2019-12-04 2021-06-10 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. COMBINATION OF BISPECIFIC FUSION PROTEIN AND ANTI-Her2 ANTIBODY FOR TUMOR TREATMENT
JP2024510111A (ja) * 2021-02-23 2024-03-06 江蘇康寧杰瑞生物制薬有限公司 腫瘍の予防、軽減、又は治療方法
WO2023070160A1 (en) * 2021-10-28 2023-05-04 Monash University Variant ctla4 proteins
WO2025085590A1 (en) * 2023-10-20 2025-04-24 Jecho Laboratories, Inc. Multifunctional pd1 fusion proteins
EP4574165A1 (en) 2023-12-21 2025-06-25 Egle Therapeutics Immunocytokine for cancer treatment
WO2025133175A1 (en) 2023-12-21 2025-06-26 Egle Therapeutics Immunocytokine for cancer treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106967172A (zh) * 2016-08-23 2017-07-21 中山康方生物医药有限公司 抗ctla4‑抗pd‑1 双功能抗体、其药物组合物及其用途
CN107400166A (zh) * 2016-05-19 2017-11-28 苏州康宁杰瑞生物科技有限公司 针对ctla4的单域抗体及其衍生蛋白

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2195342A1 (en) 2007-09-07 2010-06-16 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
EP2931747B1 (en) 2012-12-11 2020-06-10 Vib Vzw Anti-influenza antibody
US20160145355A1 (en) * 2013-06-24 2016-05-26 Biomed Valley Discoveries, Inc. Bispecific antibodies
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
CA2936244A1 (en) 2014-01-21 2015-07-30 Medimmune, Llc Compositions and methods for modulating and redirecting immune responses
US20160177284A1 (en) 2014-01-27 2016-06-23 Molecular Templates, Inc. Cell-targeted molecules comprising amino-terminus proximal or amino-terminal shiga toxin a subunit effector regions
CN105296433B (zh) * 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
PL3240801T3 (pl) 2014-12-31 2021-06-14 Checkmate Pharmaceuticals, Inc. Skojarzona immunoterapia nowotworów
WO2016197367A1 (en) 2015-06-11 2016-12-15 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
CN106397592A (zh) * 2015-07-31 2017-02-15 苏州康宁杰瑞生物科技有限公司 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
EP3356401B1 (en) 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain
US20180346571A1 (en) 2015-11-17 2018-12-06 Oncomed Pharmaceuticals, Inc. Pd-l1-binding agents and uses thereof
ES2979210T3 (es) 2015-12-15 2024-09-24 Oncoc4 Inc Anticuerpos monoclonales anti-CTLA4 humano quiméricos y humanizados y usos de los mismos
KR20180096789A (ko) * 2016-01-11 2018-08-29 인히브릭스, 인크. 다가 및 다중특이적 41bb-결합 융합 단백질
CN105754990A (zh) * 2016-01-29 2016-07-13 深圳精准医疗科技有限公司 一种pd-1/ctla-4双特异性抗体的制备方法及其应用
CN116769054A (zh) 2016-02-05 2023-09-19 奥里尼斯生物科学私人有限公司 双特异性信号传导剂及其用途
AR108377A1 (es) 2016-05-06 2018-08-15 Medimmune Llc Proteínas de unión biespecíficas y sus usos
JP7010854B2 (ja) 2016-06-14 2022-01-26 ゼンコア インコーポレイテッド 二重特異性チェックポイント阻害剤抗体
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
EP3494130A4 (en) 2016-08-03 2020-01-08 The Feinstein Institute for Medical Research C1Q AND HMGB1 FUSION PROTEINS AND USES THEREOF
US20190119636A1 (en) 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
CN111051350B (zh) 2017-09-07 2022-11-01 苏州丁孚靶点生物技术有限公司 包含信号调节蛋白α的免疫缀合物
EP3710480A4 (en) 2017-11-17 2021-12-15 Nanjing Legend Biotech Co., Ltd. SINGLE-DOMAIN ANTIBODIES AND VARIANTS OF THEM DIRECTED AGAINST PD-L1
US11773171B2 (en) 2017-12-19 2023-10-03 Surrozen Operating, Inc. WNT surrogate molecules and uses thereof
CN112399973B (zh) 2018-06-05 2022-12-16 江苏康宁杰瑞生物制药有限公司 二聚体及其用途
US12565531B2 (en) * 2019-12-04 2026-03-03 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Bispecific fusion protein for tumor treatment
WO2021110107A1 (en) * 2019-12-04 2021-06-10 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. COMBINATION OF BISPECIFIC FUSION PROTEIN AND ANTI-Her2 ANTIBODY FOR TUMOR TREATMENT

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107400166A (zh) * 2016-05-19 2017-11-28 苏州康宁杰瑞生物科技有限公司 针对ctla4的单域抗体及其衍生蛋白
CN106967172A (zh) * 2016-08-23 2017-07-21 中山康方生物医药有限公司 抗ctla4‑抗pd‑1 双功能抗体、其药物组合物及其用途

Also Published As

Publication number Publication date
US12281163B2 (en) 2025-04-22
CN112399973A (zh) 2021-02-23
US20210246210A1 (en) 2021-08-12
US11634492B2 (en) 2023-04-25
JP7359785B2 (ja) 2023-10-11
EP3802613A1 (en) 2021-04-14
TW202003588A (zh) 2020-01-16
TWI831789B (zh) 2024-02-11
JP2021526377A (ja) 2021-10-07
WO2019233413A1 (en) 2019-12-12
CN115991787A (zh) 2023-04-21
EP3802613A4 (en) 2022-03-09
US20210095031A1 (en) 2021-04-01

Similar Documents

Publication Publication Date Title
CN112399973B (zh) 二聚体及其用途
JP7504952B2 (ja) イヌ化抗体
CN112351997B (zh) 与cd19结合的重链抗体
CN110945026B (zh) 仅有重链的抗bcma抗体
CN111971090B (zh) 双特异性egfr/cd16抗原结合蛋白
WO2019096121A1 (en) Single-domain antibodies and variants thereof against pd-l1
CN111542543B (zh) 针对pd-l1的抗体及其变体
US20250051413A1 (en) Chimeric molecules comprising il-12 agonist polypeptide
EP2636685A1 (en) High affinity human antibodies to human IL-4 receptor
CN114907479B (zh) 抗cd112r抗体及其用途
JP2023549851A (ja) 葉酸受容体アルファに結合する重鎖抗体
KR20230093503A (ko) 델타 감마 사슬 매개 면역을 조절하는 조성물 및 방법
JP7712925B2 (ja) 腫瘍治療のための二重特異性融合タンパク質と抗Ｈｅｒ２抗体の組合せ
CA3228137A1 (en) Cldn18.2-targeting antibody, bispecific antibody and use thereof
KR20260032536A (ko) EpCAM에 대한 다중특이 항원 결합 단백질
AU2022207029A1 (en) Garp protein antibody and application thereof
WO2022012559A1 (zh) 抗cldn-18.2抗体及其用途
CN114746448A (zh) 用于肿瘤治疗的双特异性融合蛋白
HK40037173A (en) Dimer and use thereof
HK40037173B (en) Dimer and use thereof
CN110300763A (zh) 用于治疗白癜风的抗人cxcr3抗体
KR20260013511A (ko) 암 치료를 위한 조합 요법
CN121108361A (zh) 一种融合蛋白及其用途
CN117510641A (zh) 靶向cd112r和tigit的双特异性抗体及其用途
HK40077509A (en) Bispecific fusion protein for tumor treatment

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40037173

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant